Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Filings indexed 314 across all filing types
Latest filing 2021-07-09 Major Shareholding Noti…
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, specifically due to a bonus issue (무상증자). This type of filing is a mandatory disclosure of significant shareholding changes, which falls under the 'Major Shareholding Notification' category.
2021-07-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (DART). This document details changes in share ownership by a company executive (Yoo Won-il of Eyegene Inc.) due to a bonus share issuance. In the context of financial document classification, reports detailing personal share transactions by company directors and executives are classified as 'Director's Dealing'.
2021-07-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the acquisition of shares by major shareholders and special related parties, including the purpose of holding, funding sources, and collateral agreements. This fits the definition of a 'Major Shareholding Notification' (MRQ) as it tracks changes in significant ownership levels.
2021-07-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when company insiders (executives or major shareholders) change their shareholdings. This type of filing is categorized as 'Director's Dealing' (DIRS) in the provided schema, as it reports personal share transactions by company directors and executives.
2021-07-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a standard Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a mandatory disclosure document filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX) when company insiders (directors/major shareholders) change their shareholdings. In the provided taxonomy, this falls under 'Director's Dealing' (DIRS), which covers insider transactions and ownership reports.
2021-07-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (Korea). It details the shareholding changes of an executive (Yun Hyung Su) at Eyegene Inc. due to a capital increase. This type of filing is a standard regulatory disclosure for insider transactions, which falls under the 'Director's Dealing' category.
2021-07-05 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.